dilazep has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Kaochar, S | 1 |
Rusin, A | 1 |
Foley, C | 1 |
Rajapakshe, K | 1 |
Robertson, M | 1 |
Skapura, D | 1 |
Mason, C | 1 |
Berman De Ruiz, K | 1 |
Tyryshkin, AM | 1 |
Deng, J | 1 |
Shin, JN | 1 |
Fiskus, W | 1 |
Dong, J | 1 |
Huang, S | 1 |
Navone, NM | 1 |
Davis, CM | 1 |
Ehli, EA | 1 |
Coarfa, C | 1 |
Mitsiades, N | 1 |
1 other study available for dilazep and Androgen-Independent Prostatic Cancer
Article | Year |
---|---|
Inhibition of GATA2 in prostate cancer by a clinically available small molecule.
Topics: Cell Line, Tumor; Chromatin; Dilazep; GATA2 Transcription Factor; Gene Expression Regulation, Neopla | 2021 |